Banco Santander, S.A. Press Releases

SAN 
$9.82
*  
0.02
 negative 
0.2%
Get SAN Alerts
*Delayed - data as of Apr. 17, 2014 
Exchange: NYSE
Industry: Finance
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Basketball Hall of Famer Nancy Lieberman Teams Up with New Nasacort® Allergy 24HR to Help Allergy Sufferers Put the Full 'Cort Press on Nasal Allergy Symptoms
4/15/2014 9:00:00 AM - PR Newswire

Santander Holdings USA Declares Quarterly Dividend On Preferred Stock
4/14/2014 1:26:00 PM - PR Newswire

Santander Appoints Jerry Plush As CFO And Maria Tedesco As Head Of Retail Banking
4/8/2014 10:00:00 AM - PR Newswire

Technical Briefing on Equities Reaching New High -- Research on Quanta Services, Southwestern Energy, Ingram Micro, and Banco Santander
4/7/2014 12:24:00 PM - PR Newswire

Sanofi: Genzyme to Resubmit Lemtrada Application for FDA Review
4/7/2014 1:05:00 AM - GlobeNewswire

Genzyme to Resubmit LemtradaTM Application for FDA Review
4/7/2014 1:00:00 AM - Business Wire

Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age
4/1/2014 9:13:00 AM - PR Newswire

Sanofi and Regeneron Report Positive Results With Alirocumab From Phase 2 Japanese Study
4/1/2014 8:00:00 AM - PR Newswire

Sanofi Appoints Dr. Anne C. Beal to the Newly Created Position of Chief Patient Officer
3/31/2014 1:08:00 AM - GlobeNewswire

Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session
3/27/2014 2:00:00 AM - PR Newswire

Santander Holdings USA Would Maintain Capital Strength Through Most Adverse Scenario, Stress Test Finds
3/26/2014 6:35:00 PM - PR Newswire

U.S. Prescribing Information for Thyrogen Revised to Include Use of Wider Range of Radioiodine in Patients
3/26/2014 2:00:00 PM - Business Wire

Genzyme’s Lemtrada™ Approved in Brazil for Treatment of Multiple Sclerosis
3/21/2014 8:00:00 AM - Business Wire

Over 350 Business Leaders Discuss Economy At Joint Santander And Greater Boston Chamber Of Commerce Event
3/20/2014 3:38:00 PM - PR Newswire

Santander Kicks Off Tribeca Film Festival® Sponsorship With Sweepstakes Giving 20 Winners A Chance To Attend Private Film Screening
3/19/2014 11:29:00 AM - PR Newswire

Most Active Stocks Scanner: NII Holdings, Banco Santander, Frontier Communications, and Newell Rubbermaid
3/18/2014 9:31:00 AM - PR Newswire

Multiple Sclerosis Association of America's Nationwide Search Uncovers Inspiring Stories of People Living with MS Who Swim for Better Health
3/18/2014 9:00:00 AM - PR Newswire

The Securities Arbitration Law Firm of Klayman & Toskes and Carlo Law Offices File $1.5 Million Claim Against Santander Securities to Recover Losses Sustained in Puerto Rico Bonds and First Puerto Rico Funds -- SAN
3/14/2014 11:55:00 AM - GlobeNewswire

Inactivated Polio Vaccines Broadly Available for the World's Children in the Drive Toward Polio Eradication
3/3/2014 1:00:00 AM - PR Newswire

Genzyme Recognizes International Rare Disease Day with Global Awareness Programs and Launch of Fourth Annual Patient Advocacy Leadership (PAL) Awards
2/28/2014 1:00:00 AM - Business Wire

Alnylam Announces Closing of Previously Announced Alliance with Genzyme for Discovery, Development, and Commercialization of RNAi Therapeutics as Genetic Medicines
2/27/2014 5:00:00 PM - Business Wire

New National Survey: Majority of Moms Hold Incorrect Beliefs About Head Lice Management and Treatment
2/26/2014 8:05:00 AM - PR Newswire

Ardelyx Licenses NaP2b Phosphate Inhibitor Program for Kidney Disease to Sanofi in Deal Worth up to $198 Million
2/24/2014 9:00:00 AM - Market Wire

Sanofi Returns to Growth in Q4 2013
2/6/2014 7:00:00 AM - PR Newswire

Sanofi FY 2013 - Interview with CEO Chris Viehbacher
2/6/2014 1:56:00 AM - Business Wire